XM does not provide services to residents of the United States of America.

EU approves biggest grant yet under Chips Act for TSMC Germany plant



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>CORRECTED-UPDATE 2-EU approves biggest grant yet under Chips Act for TSMC Germany plant</title></head><body>

Corrects text and instrument codes in paragraph 5 to show Robert Bosch of Germany is a stakeholder, not Bosch Ltd. of India

BRUSSELS, Aug 20 (Reuters) -The European Commission said on Tuesday it had approved 5 billion euros ($5.5 billion) in German state aid to support a new microchip plant in Dresden for the European Semiconductor Manufacturing Company (ESMC).

The award for the project led by Taiwan's TSMC 2330.tw is the biggest state subsidy granted so far under the EU Chips Act, and Germany's first.

"This is a true win-win situation for all of us," EU Commission's President Ursula von der Leyen said during the inauguration ceremony for the plant.

German Economy Minister Robert Habeck praised the decision and said his government would maintain the fast pace of the project, which targets production in 2027, and finalise funding.

ESMC is a joint venture led by TSMC, the world's largest contract chipmaker, with European firms Robert Bosch, Infineon IFXGn.DE and NXP NXPI.O each taking a 10% stake.

The Dresden facility is forecast to cost 10 billion euros in total to build.

"The facility will operate as an open foundry, meaning that any customer – including but not limited to the three other shareholders besides TSMC – can place orders for the production of specific chips," the Commission said in a statement announcing the subsidy approval.

Although the ESMC plant will be making generations of chips slightly behind the most advanced technology used in AI chips and smartphones, it will add capacity in the range that is most important for automotive and other industrial applications key to European manufacturing.

The plant should improve Europe's resiliency against a future chip shortage of the type experienced during the COVID pandemic.

($1 = 0.9025 euros)



Reporting by Sudip Kar-Gupta in Brussels, Andrey Sychev in Gdansk, Toby Sterling in Amsterdam; Editing by Kirsten Donovan, Rachel More and David Evans

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.